Eli Lilly and Company
LLYFinancial Statements
Income Statement (Annual)
Amounts in millions
2024
12/31/2024
Revenue
45,043
Cost of Revenue
8,418
Gross Profit
36,624
Gross Margin
81.3%
Operating Income
17,502
Operating Margin
38.9%
Net Income
10,590
Net Margin
23.5%
EPS (Basic)
$11.76
EPS (Diluted)
$11.71
EBITDA
15,228
EBITDA Margin
33.8%
2023
12/31/2023
Revenue
34,124
Cost of Revenue
7,082
Gross Profit
27,042
Gross Margin
79.2%
Operating Income
10,787
Operating Margin
31.6%
Net Income
5,240
Net Margin
15.4%
EPS (Basic)
$5.83
EPS (Diluted)
$5.80
EBITDA
8,568
EBITDA Margin
25.1%
2022
12/31/2022
Revenue
28,541
Cost of Revenue
6,630
Gross Profit
21,912
Gross Margin
76.8%
Operating Income
8,653
Operating Margin
30.3%
Net Income
6,245
Net Margin
21.9%
EPS (Basic)
$6.57
EPS (Diluted)
$6.57
EBITDA
8,661
EBITDA Margin
30.3%
2021
12/31/2021
Revenue
28,318
Cost of Revenue
7,313
Gross Profit
21,006
Gross Margin
74.2%
Operating Income
7,933
Operating Margin
28.0%
Net Income
5,582
Net Margin
19.7%
EPS (Basic)
$5.85
EPS (Diluted)
$5.85
EBITDA
8,043
EBITDA Margin
28.4%
2020
12/31/2020
Revenue
24,540
Cost of Revenue
5,483
Gross Profit
19,057
Gross Margin
77.7%
Operating Income
7,211
Operating Margin
29.4%
Net Income
6,194
Net Margin
25.2%
EPS (Basic)
$6.47
EPS (Diluted)
$6.47
EBITDA
8,913
EBITDA Margin
36.3%